The global Disease-Modifying Antirheumatic Drug (DMARD) Market is estimated to be valued at US$ 21.42 Bn in 2023 and is expected to exhibit a CAGR of 3.6% over the forecast period 2028 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Disease-Modifying Antirheumatic Drugs (DMARDs) are a class of drugs that are used to help slow the progression of autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis. DMARDs work by modifying or controlling the disease process and help prevent further joint damage. These drugs suppress the immune system and reduce symptoms like pain, swelling and stiffness.
Market key trends:
One of the key trends in the DMARD market is increased research for newer generation DMARDs for treating psoriatic arthritis. Psoriatic arthritis is a chronic inflammatory disease associated with psoriasis. According to estimations by the National Psoriasis Foundation, around 30% of people with psoriasis may develop psoriatic arthritis. Currently available DMARDs are unable to provide long term relief for psoriatic arthritis symptoms. Drug manufacturers are investing in research and clinical trials for newer targeted DMARDs with novel mechanisms of action for better management of psoriatic arthritis.
Segment Analysis
The global disease-modifying antirheumatic drug (DMARD) market is segmented into origin, route of administration, drug class, indication, end user, and distribution channel. Based on origin, the market is bifurcated into biological and non-biological DMARDs. The non-biological DMARDs segment currently dominates the market due to their affordable costs and ease of availability. However, the biological DMARDs segment is expected to witness higher growth during the forecast period owing to the better efficacy of these drugs over non-biological ones.
Key Takeaways
The global disease-modifying antirheumatic drug (DMARD) market size was valued at US$ 21.42 billion in 2023. It is expected to grow at a substantial CAGR of 3.6% during the forecast period. The growth is being driven by the increasing prevalence of rheumatoid arthritis and other autoimmune disorders across the world.
Regional analysis: North America dominates the global DMARD market currently due to advanced healthcare facilities and high treatment rates in the region. It is followed by Europe. However, Asia Pacific is expected to witness the highest growth over 2028-2030 owing to increasing healthcare investments, rising awareness regarding autoimmune conditions, and growing penetration of key market players in countries such as China and India.
Key players: Key players operating in the DMARD market include Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc. These companies collectively account for a significant portion of the overall market revenue. Sanofi. leads the market with strong product offerings across drug classes.
No comments:
Post a Comment